Article

The emerging phenomenon of electronic cigarettes

Centro per la Prevenzione e Cura del Tabagismo, Azienda Ospedaliero-Universitaria Policlinico-Vittorio Emanuele, Università di Catania, Catania, Italy.
Expert Review of Respiratory Medicine 02/2012; 6(1):63-74. DOI: 10.1586/ers.11.92
Source: PubMed

ABSTRACT The need for novel and more effective approaches to tobacco control is unquestionable. The electronic cigarette is a battery-powered electronic nicotine delivery system that looks very similar to a conventional cigarette and is capable of emulating smoking, but without the combustion products accountable for smoking's damaging effects. Smokers who decide to switch to electronic cigarettes instead of continuing to smoke would achieve large health gains. The electronic cigarette is an emerging phenomenon that is becoming increasingly popular with smokers worldwide. Users report buying them to help quit smoking, to reduce cigarette consumption, to relieve tobacco withdrawal symptoms due to workplace smoking restrictions and to continue to have a 'smoking' experience but with reduced health risks. The focus of the present article is the health effects of using electronic cigarettes, with consideration given to the acceptability, safety and effectiveness of this product to serve as a long-term substitute for smoking or as a tool for smoking cessation.

Download full-text

Full-text

Available from: Pasquale Caponnetto, Oct 23, 2014
8 Followers
 · 
514 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Das Deutsche Krebsforschungszentrum rät vom Konsum der elektrischen Zigarette ab: Unklar ist die Wirkung auf die Gesundheit, und auch als Hilfsmittel zur Tabakentwöhnung ist sie nicht geeignet.
    Deutsches Arzteblatt 109(43):A1222. · 3.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The "electronic (e-)cigarette" generates intense scientific debate about its use. Its popularity is increasing worldwide as a method to reduce/quit smoking, and to smoke indoors when restrictions on smoking tobacco are present. WHO recommends caution, until its effectiveness in helping smokers is clarified, and the possible harm evaluated. The aim of this study was to assess the content of the aromatic liquid mixture and its vapour and the Particulate Matter (PM) emissions of an Italian brand of e-cigarette and to compare its PM emissions with a conventional cigarette. Propylene glycol (66%) and glycerine (24%) were main components in the liquid, while the flavouring substances were less than 0.1%. The same substances were detected in the vapour in similar proportions. Fine and ultrafine PM emissions were higher for the conventional versus the e-cigarette (e.g.: PM10=922 vs 52 microg/m3; PM1=80 vs 14 microg/m3). The e-cigarette seems to give some advantages when used instead of the conventional cigarette, but studies are still scanty: it could help smokers to cope with some of the rituals associated with smoking gestures and to reduce or eliminate tobacco consumption avoiding passive smoking. However, the e-cigarette causes exposure to different chemicals compared with conventional cigarettes and thus there is a need for risk evaluation for both e-cigarettes and passive steam exposure in smokers and non smokers.
    Annali di igiene: medicina preventiva e di comunità 11/2011; 24(4):279-88.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Smoking is the leading cause of premature mortality in western countries and it is important for smokers to stop as early as possible. Several approaches for cessation are available but they lack high levels of efficacy. Consequently, there is a compelling need for more effective approaches and safer medications to aid smokers in achieving long-term abstinence. Expanding knowledge in our understanding of the mechanisms involved in tobacco dependence is leading to the development of novel therapies and vaccines for smoking cessation, many of which are currently in the advanced stage of development and offer promise. Here we will review efficacy and safety data from human clinical trials of current and emerging therapies and tools which are approved or undergoing investigation.
    Current Opinion in Pharmacology 03/2012; 12(3):229-37. DOI:10.1016/j.coph.2012.02.005 · 4.23 Impact Factor
Show more